Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FC084CSA and Tislelizumab in Advanced Malignant Solid Tumors
NCT06499350Phase 2Recruiting
- Sponsor
- FindCure Biosciences
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FC084CSA in solid tumor and non-small cell lung cancer (NSCLC), sponsored by FindCure Biosciences. Primary endpoints: Maximum Tolerated Dose at 8 months, Recommended Phase 2 Dose at 8 months and 2 more. Started Nov 2024; status: recruiting.
02
Drugs
FC084CSA
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06499350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06499350.